Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717013 · ClinicalTrials.gov registry record · NA
The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism
A NA study, sponsored by Metabolic Technologies.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02717013 is a NA study that was terminated before completion, run by Metabolic Technologies. The registered enrollment target is 10 participants.
The verdict
NCT02717013, a NA study, was terminated before completion, sponsored by Metabolic Technologies.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will determine the effects of supplementing beta-hydroxy-beta-methylbutyrate (HMB) on body composition and strength changes during weight loss. When overweight and obese persons lose weight, and in particular in conjunction with dietary restrictions, muscle, bone mass, and muscle strength are also lost. HMB has been shown to preserve muscle mass and strength, and it is thought that HMB may also preserve muscle, bone, and strength during weight-loss.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT HMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717013
The ClinicalTrials.gov registry entry for NCT02717013 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Technologies, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02717013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02717013 about?
NCT02717013 is a clinical study titled "The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism". This study will determine the effects of supplementing beta-hydroxy-beta-methylbutyrate (HMB) on body composition and strength changes during weight loss. When overweight and obese persons lose weight, and in particular in conjunction with dietary restrictions, muscle, bone mass, and muscle strength...
What is the current status of trial NCT02717013?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2016-03. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02717013?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), HMB (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02717013?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.